Skip to main content
. 2019 Oct 4;104(11):2144–2154. doi: 10.3324/haematol.2018.208603

Figure 2.

Figure 2.

Proposed algorithm for first-line treatment using approved options in clinical practice. y: years; R: rituximab; FCR: fluradabine, cyclophosphamide, rituximab; BR: bendamustine, rituximab; Clb-G: chlorambucil, obinutuzumab.